Catalyst Pharmaceutical
CPRX
CPRX was delisted on the 14th of July, 2026.
85 hedge funds and large institutions have $104M invested in Catalyst Pharmaceutical in 2015 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 29 increasing their positions, 18 reducing their positions, and 14 closing their positions.
61% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 18
6% less funds holding
Funds holding: 90 → 85 (-5)
23% less capital invested
Capital invested by funds: $134M → $104M (-$30.6M)
36% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 14
77% less call options, than puts
Call options by funds: $3K | Put options by funds: $13K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
+$2.69M |
| 2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$1.02M |
| 3 |
Millennium Management
New York
|
+$671K |
| 4 |
D.E. Shaw & Co
New York
|
+$509K |
| 5 |
State Street
Boston,
Massachusetts
|
+$293K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
-$8.35M |
| 2 |
HM
HealthCor Management
New York
|
-$1.16M |
| 3 |
TI
Turner Investments
Berwyn,
Pennsylvania
|
-$1.1M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$1.1M |
| 5 |
CCI
Columbus Circle Investors
|
-$419K |
CPRX Hedge Fund Activity: Q4 2015 in Review
85 of the 3,824 institutional investors tracked by Wall St. Rank reported a position in Catalyst Pharmaceutical (CPRX) for Q4 2015, worth a combined $104M — down 23% from $134M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of CPRX and 9 opened new positions — a net loss of 5 holders — while 18 trimmed existing stakes and 29 added.
The largest buyer was Baker Bros. Advisors, adding an estimated $2.69M. The largest seller was Consonance Capital Management, cutting an estimated $8.35M.
- 85 institutional investors held Catalyst Pharmaceutical (CPRX) as of Q4 2015, down from 90 in Q3 2015.
- Funds reported $104M of Catalyst Pharmaceutical stock for Q4 2015, down 23% quarter-over-quarter.
- 9 funds opened new Catalyst Pharmaceutical positions in Q4 2015 and 14 closed out, a net change of -5 holders.
- The largest Catalyst Pharmaceutical buyer in Q4 2015 was Baker Bros. Advisors, an estimated $2.69M added.
- The largest Catalyst Pharmaceutical seller in Q4 2015 was Consonance Capital Management, an estimated $8.35M sold.
Based on aggregated 13F filings for Q4 2015.